Home Stock

Stock Research: Hanall Biopharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Hanall Biopharma

KSC:009420 KR7009420001
61
  • Value
    16
  • Growth
    75
  • Safety
    Safety
    34
  • Combined
    31
  • Sentiment
    92
  • 360° View
    360° View
    61
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Hanall Biopharma Co Ltd is a Korea-based company that manufactures and distributes synthetic pharmaceuticals and biopharmaceuticals. The company operates in the pharmaceutical industry, producing drugs for various conditions including diabetes, skin issues, and cardiovascular diseases. It distributes its products in domestic and overseas markets. In the last fiscal year, the company had a market cap of $993 million, profits of $50 million, and revenue of $94 million.

more

ANALYSIS: With an Obermatt 360° View of 61 (better than 61% compared with alternatives), overall professional sentiment and financial characteristics for the stock Hanall Biopharma are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Hanall Biopharma. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 75% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 92, which means that professional investors are more optimistic about the stock than for 92% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 16, which means that the share price of Hanall Biopharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 84% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 34, which means that the company has a financing structure that is riskier than those of 66% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Sales (P/S)
Weakest Rank Price vs. Earnings (P/E)
Country South Korea
Industry Pharmaceuticals
Size Small
Website hanall.co.kr
Index
KOSPI
Hanall Biopharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 17-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 4 4 7
Growth
75 100 99 1
Safety
Safety
34 59 72 74
Sentiment
92 54 78 63
360° View
360° View
61 56 79 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
86 76 76 100
Opinions Change
50 50 50 50
Pro Holdings
n/a 36 64 1
Market Pulse
61 48 63 60
Sentiment
92 54 78 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 4 4 7
Growth
75 100 99 1
Safety Safety
34 59 72 74
Combined
31 55 60 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
1 7 5 9
Price vs. Earnings (P/E)
100 1 3 9
Price vs. Book (P/B)
1 8 5 9
Dividend Yield
1 1 1 1
Value
16 4 4 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
44 87 44 38
Profit Growth
8 98 100 18
Capital Growth
100 84 89 12
Stock Returns
98 72 100 7
Growth
75 100 99 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
67 93 93 92
Refinancing
6 12 19 23
Liquidity
54 63 70 84
Safety Safety
34 59 72 74

Similar Stocks

Discover high‑ranked alternatives to Hanall Biopharma and broaden your portfolio horizons.

Shimadzu

TYO:7701
Country: Japan
Industry: Electronic Equipment
Size: X-Large
Full Stock Analysis

Cosmo Energy Holdings

TYO:5021
Country: Japan
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

NICE Information Service

KSC:030190
Country: South Korea
Industry: Research & Consulting
Size: Medium
Full Stock Analysis

Hyundai Home Shopping Network

KSC:057050
Country: South Korea
Industry: Internet Retail
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews